Data protection Impressum

Biotech

A new EY study ranks Switzerland 3rd worldwide for corporate R&D intensity and 6th for total spending, with 14 Swiss companies among the global top 500.

Business environment

Switzerland ranks 3rd globally for corporate R&D intensity

18 May 2026

The Swiss Biotech Report 2026 reveals record sector revenues and a landmark year for private funding, as talent and international collaboration continue to underpin Switzerland's position at the forefront of global life sciences.

Swiss Biotech Report 2026: talent and tenacity drive record performance

5 May 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2026)

29 April 2026

Lausanne-based AC Immune has amended its license and collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative diseases, with IND-enabling studies set to commence in the first half of 2026.

AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy

15 April 2026

Four life sciences projects were recognized at BIND – BioInnovation Day 2026, held at CHUV Lausanne on 1 April 2026, as the region's flagship academic innovation showcase drew 340 participants from academia, healthcare, industry, and investment.

BIND 2026 highlights Western Switzerland’s life sciences innovation pipeline

14 April 2026

Global in vitro diagnostics leader bioMérieux has invested over CHF 1 million in Geneva-based scale-up Plair, whose RAPID-C+ system is setting a new standard for real-time viable particle monitoring in pharmaceutical cleanrooms.

bioMérieux invests in Plair to advance environmental monitoring in pharma

30 March 2026

The canton of Fribourg hosted the international BIOKET conference for the first time in Switzerland from 17-19 March 2026, a milestone that reflects its growing standing as one of Europe's most dynamic bioeconomy ecosystems.

The canton of Fribourg makes its mark at BIOKET 2026

18 March 2026

Alithea Genomics has completed its seed financing round with an additional CHF 3 million, bringing the total to CHF 6.9 million, to accelerate the commercialization of its large-scale RNA sequencing platforms for drug screening and toxicology.

Alithea Genomics raises CHF 6.9 million to industrialize RNA sequencing

9 March 2026

As life sciences companies navigate increasingly complex global markets, the decision of where to establish or expand international operations has become a strategic one.

Why Life Sciences Companies Choose Switzerland to Scale Internationally

Lausanne-based Xsensio has closed an oversubscribed USD 7 million Series A financing round to accelerate clinical deployment of its Lab-on-Skin wearable biosensing platform, with new backing from WI Harper and a collaboration with Texas Instruments.

Xsensio raises USD 7 million to advance its wearable biosensing platform

3 March 2026

1 2 3 4 5 … 18